雄性激素暴露、多囊卵巢综合征与患有中央浆液性脉络膜视网膜病变的跨血缘个体之间的关系。

IF 4.4 Q1 OPHTHALMOLOGY Ophthalmology. Retina Pub Date : 2024-11-07 DOI:10.1016/j.oret.2024.10.026
Jonathan D Shirian, Jacqueline K Shaia, Nikhil Das, Katherine E Talcott, Rishi P Singh, Danny A Mammo
{"title":"雄性激素暴露、多囊卵巢综合征与患有中央浆液性脉络膜视网膜病变的跨血缘个体之间的关系。","authors":"Jonathan D Shirian, Jacqueline K Shaia, Nikhil Das, Katherine E Talcott, Rishi P Singh, Danny A Mammo","doi":"10.1016/j.oret.2024.10.026","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>or Purpose: The prevalence of central serous chorioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed patients remains largely unexplored. While these groups involve patients with elevated testosterone levels, previous literature is inconclusive on the influence of testosterone on CSCR. This study aimed to determine the relationship between CSCR and cohorts with exogenous androgen exposure, female-to-male (FTM) transgender individuals, and those diagnosed with PCOS.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Subjects: </strong>Patients with CSCR, receiving exogenous androgens, FTM transgender individuals (defined as gender identity disorder (GID), endocrine disorder not otherwise specified, sex-discordant hormone therapy, and FTM surgery), and patients with PCOS.</p><p><strong>Methods: </strong>An electronic health records platform of over 100 million patients was examined for this study. Patients were identified through ICD-10 and procedural codes. Patients with prior steroid prescriptions, anxiety disorders, and fluticasone use were excluded. Prevalence and prevalence odds ratios (OR) of comorbid CSCR were calculated utilizing R Studio and 95% confidence intervals (CI) were calculated.</p><p><strong>Main outcome measures: </strong>Prevalence, prevalence ORs, and 95% CIs of CSCR.</p><p><strong>Results: </strong>Among 21,056 CSCR patients, the mean age was 61 years [SD±15], with 67.95% being male. The prevalence of CSCR was highest among those receiving exogenous androgen therapy (24.13 per 1,000 CSCR patients; OR: 5.84, 95% CI: 5.35-6.37). The FTM surgery (OR: 3.04) and sex discordant hormone therapy (OR: 5.32) cohorts also showed significant associations with CSCR (p < 0.05). PCOS patients had a more limited but still significant association (OR: 1.23, 95% CI: 1.013-1.49). GID did not show a significant relationship with CSCR (p > 0.05).</p><p><strong>Conclusions: </strong>This study which investigated the associations between FTM transgender, PCOS patients, and CSCR demonstrates that conditions linked with elevated androgens are associated with higher odds of CSCR. These findings emphasize the value of ophthalmic screenings in these populations, particularly within the transgender healthcare community.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations Between Androgen Exposure, PCOS, and Transmasculine Individuals with Central Serous Chorioretinopathy.\",\"authors\":\"Jonathan D Shirian, Jacqueline K Shaia, Nikhil Das, Katherine E Talcott, Rishi P Singh, Danny A Mammo\",\"doi\":\"10.1016/j.oret.2024.10.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>or Purpose: The prevalence of central serous chorioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed patients remains largely unexplored. While these groups involve patients with elevated testosterone levels, previous literature is inconclusive on the influence of testosterone on CSCR. This study aimed to determine the relationship between CSCR and cohorts with exogenous androgen exposure, female-to-male (FTM) transgender individuals, and those diagnosed with PCOS.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Subjects: </strong>Patients with CSCR, receiving exogenous androgens, FTM transgender individuals (defined as gender identity disorder (GID), endocrine disorder not otherwise specified, sex-discordant hormone therapy, and FTM surgery), and patients with PCOS.</p><p><strong>Methods: </strong>An electronic health records platform of over 100 million patients was examined for this study. Patients were identified through ICD-10 and procedural codes. Patients with prior steroid prescriptions, anxiety disorders, and fluticasone use were excluded. Prevalence and prevalence odds ratios (OR) of comorbid CSCR were calculated utilizing R Studio and 95% confidence intervals (CI) were calculated.</p><p><strong>Main outcome measures: </strong>Prevalence, prevalence ORs, and 95% CIs of CSCR.</p><p><strong>Results: </strong>Among 21,056 CSCR patients, the mean age was 61 years [SD±15], with 67.95% being male. The prevalence of CSCR was highest among those receiving exogenous androgen therapy (24.13 per 1,000 CSCR patients; OR: 5.84, 95% CI: 5.35-6.37). The FTM surgery (OR: 3.04) and sex discordant hormone therapy (OR: 5.32) cohorts also showed significant associations with CSCR (p < 0.05). PCOS patients had a more limited but still significant association (OR: 1.23, 95% CI: 1.013-1.49). GID did not show a significant relationship with CSCR (p > 0.05).</p><p><strong>Conclusions: </strong>This study which investigated the associations between FTM transgender, PCOS patients, and CSCR demonstrates that conditions linked with elevated androgens are associated with higher odds of CSCR. These findings emphasize the value of ophthalmic screenings in these populations, particularly within the transgender healthcare community.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2024.10.026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2024.10.026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目标:或目的:经典型、多囊卵巢综合征(PCOS)和雄激素暴露患者中中央浆液性脉络膜视网膜病变(CSCR)的发病率在很大程度上仍未得到探讨。虽然这些群体中的患者睾酮水平升高,但以往的文献对睾酮对 CSCR 的影响尚无定论。本研究旨在确定CSCR与外源性雄激素暴露人群、女变男(FTM)变性人以及被诊断为多囊卵巢综合征的人群之间的关系:设计:横断面研究:研究对象:接受外源性雄激素治疗的 CSCR 患者、女变男(FTM)变性人(定义为性别认同障碍(GID)、内分泌失调(未另作规定)、性别不一致的激素治疗和 FTM 手术)以及 PCOS 患者:本研究使用了一个包含 1 亿多名患者的电子健康记录平台。通过 ICD-10 和程序代码确定患者身份。排除了既往有类固醇处方、焦虑症和使用氟替卡松的患者。利用 R Studio 计算了合并 CSCR 的患病率和患病几率比(OR),并计算了 95% 的置信区间(CI):主要结果测量指标:CSCR的患病率、患病率OR和95%置信区间:在 21056 名 CSCR 患者中,平均年龄为 61 岁 [SD±15],67.95% 为男性。接受外源性雄激素治疗的患者中,CSCR发病率最高(每千名CSCR患者中有24.13例;OR:5.84,95% CI:5.35-6.37)。FTM手术(OR:3.04)和性别不一致的激素治疗(OR:5.32)队列也显示出与CSCR的显著相关性(P < 0.05)。多囊卵巢综合症患者的相关性虽然有限,但仍然很重要(OR:1.23,95% CI:1.013-1.49)。GID与CSCR无明显关系(P > 0.05):这项研究调查了FTM变性人、多囊卵巢综合征患者与CSCR之间的关系,结果表明,与雄激素升高有关的疾病与CSCR的高发几率相关。这些发现强调了在这些人群中进行眼科筛查的价值,尤其是在变性人医疗群体中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Associations Between Androgen Exposure, PCOS, and Transmasculine Individuals with Central Serous Chorioretinopathy.

Objective: or Purpose: The prevalence of central serous chorioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed patients remains largely unexplored. While these groups involve patients with elevated testosterone levels, previous literature is inconclusive on the influence of testosterone on CSCR. This study aimed to determine the relationship between CSCR and cohorts with exogenous androgen exposure, female-to-male (FTM) transgender individuals, and those diagnosed with PCOS.

Design: Cross-sectional study.

Subjects: Patients with CSCR, receiving exogenous androgens, FTM transgender individuals (defined as gender identity disorder (GID), endocrine disorder not otherwise specified, sex-discordant hormone therapy, and FTM surgery), and patients with PCOS.

Methods: An electronic health records platform of over 100 million patients was examined for this study. Patients were identified through ICD-10 and procedural codes. Patients with prior steroid prescriptions, anxiety disorders, and fluticasone use were excluded. Prevalence and prevalence odds ratios (OR) of comorbid CSCR were calculated utilizing R Studio and 95% confidence intervals (CI) were calculated.

Main outcome measures: Prevalence, prevalence ORs, and 95% CIs of CSCR.

Results: Among 21,056 CSCR patients, the mean age was 61 years [SD±15], with 67.95% being male. The prevalence of CSCR was highest among those receiving exogenous androgen therapy (24.13 per 1,000 CSCR patients; OR: 5.84, 95% CI: 5.35-6.37). The FTM surgery (OR: 3.04) and sex discordant hormone therapy (OR: 5.32) cohorts also showed significant associations with CSCR (p < 0.05). PCOS patients had a more limited but still significant association (OR: 1.23, 95% CI: 1.013-1.49). GID did not show a significant relationship with CSCR (p > 0.05).

Conclusions: This study which investigated the associations between FTM transgender, PCOS patients, and CSCR demonstrates that conditions linked with elevated androgens are associated with higher odds of CSCR. These findings emphasize the value of ophthalmic screenings in these populations, particularly within the transgender healthcare community.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
期刊最新文献
Transient Monocular Visual Loss Captured by OCT Angiography. Ocular Manifestations of Pallister-Killian Syndrome. Resolution of Angiographic Macular Leakage with Faricimab Versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Outcomes and Need for Additional Interventions Following Intravitreal Bevacizumab for Retinopathy of Prematurity. Real-World Functional Outcomes and Quality of Life in Geographic Atrophy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1